Advanced nanotechnology: An arsenal to enhance immunotherapy in fighting cancer

Cheng, Chun-Ting; Castro, Gabriel Dias de; Liu, Chun-Hsin; Lau, Pauline Y

doi:10.1016/j.cca.2019.01.027

Cited by 33 publications

(28 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 In vitro cell cycle and apoptotic analyses for MC-38 cells treated with different configurations (1: control, 2: free PTX, 3: Eu-s/PTX, and 4: Eu-FBCP/PTX). a Cell cycle analysis results from the different treatments (1)(2)(3)(4). Brdu and PI were used to calculate the cell fractions for each phase (G1, S, or G2/M) in the cell cycle.…”

Section: Caveolin-mediated Endocytosismentioning

confidence: 99%

“…d, e FACS profiles and the quantified data from JC-1 staining exhibiting changes in mitochondrial membrane potential for the 24 h-treated (1-4) cells (n = 3). f, g Representative expression of p53, Bcl-2, Bax, Cyt c, cleaved caspase-9, and cleaved caspase-3 in the treated cells (1)(2)(3)(4). h Schematic of a plausible mechanism for the apoptosis in the treated cells (1-4) based on the expression (f, g).…”

Section: Caveolin-mediated Endocytosismentioning

confidence: 99%

“…h Schematic of a plausible mechanism for the apoptosis in the treated cells (1-4) based on the expression (f, g). i Representative microscopic AO/PI-stained cell images from live/dead assay with the treatments (1)(2)(3)(4) fluorescence (24.9%). For the treatment with Eu-FBCP/ PTX, this inverse proportion eventually reached 46.5% and 53.7% red and green fluorescence, respectively, suggesting that the greatest disruption in ΔΨ m (mitochondrial damage) of the cancer cells can be driven by Eu-FBCP/PTX treatment.…”

Section: Caveolin-mediated Endocytosismentioning

confidence: 99%

“…The recent approval of several immune-stimulatable or modulatable formulations to induce immunogenic cell death (ICD) for cancer treatments led to many attempts, including in clinical trials, to overcome the severe side effects of conventional cancer monotherapies [1][2][3]. The direct application of immunoreactive formulations often required a high dosage to secure immunotherapeutic efficacy; however, this approach induced unpredictable responses and adverse effects from the systemic immune activations, undesirable interactions between the formulations and host immune systems, and formulation instabilities [4]. Similar to the development of a drug delivery system (DDS), recent engineering attempts have been made to fabricate nanosystems for delivering immunoreactive formulations for the targeted release of antigens, adjuvants, or chemo-drugs to mitigate the limitations [5,6].…”

Section: Introductionmentioning

confidence: 99%

“…a Representative expression of HMGB1 and CRT from the treatments (1-4), indicating the induction of ICD. b CD11c + -CD86 + (as indicators of DC maturation) plots to identify maturation of the DCs by exposure to TAA generated from the treated cells(1)(2)(3)(4). c CFSE-IFN-γ plots to determine the proliferation and activation of CD8 + T cells.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Artificial Nanoscale Erythrocytes from Clinically Relevant Compounds for Enhancing Cancer Immunotherapy

Nam

Park

et al. 2020

Nano-Micro Lett.

View full text Add to dashboard Cite

ARTICLE HIGHLIGHTS• A two-phase coaxial electrospray was designed to produce paclitaxel-loaded fake blood cell Eudragit particles (Eu-FBCP/PTX).• The chemo-immunotherapeutic efficacy was further enhanced after combining with anti-programmed death-ligand 1 antibodies (Eu-FBCP/PTX + aPL).ABSTRACT Because of enhanced efficacy and lower side effects, cancer immunotherapies have recently been extensively investigated in clinical trials to overcome the limitations of conventional cancer monotherapies. Although engineering attempts have been made to build nanosystems even including stimulus nanomaterials for the efficient delivery of antigens, adjuvants, or anticancer drugs to improve immunogenic cancer cell death, this requires huge R&D efforts and investment for clinically relevant findings to be approved for translation of the nanosystems. To this end, in this study, an air-liquid two-phase electrospray was developed for stable bubble pressing under a balance between mechanical and electrical parameters of the spray to continuously produce biomimetic nanosystems consisting of only clinically relevant compounds [paclitaxel-loaded fake blood cell Eudragit particle (Eu-FBCP/PTX)] to provide a conceptual leap for the timely development of translatable chemo-immunotherapeutic nanosystems. This was pursued as the efficacy of systems for delivering anticancer agents that has been mainly influenced by nanosystem shape because of its relevance to transporting behavior to organs, blood circulation, and cell-membrane interactions. The resulting Eu-FBCP/PTX nanosystems exhibiting phagocytic and micropinocytic uptake behaviors can confer better efficacy in chemo-immunotherapeutics in the absence and presence of anti-PD-L1 antibodies than similar sized PTX-loaded spherical Eu particles (Eu-s/PTX).

show abstract

Section: Caveolin-mediated Endocytosismentioning

confidence: 99%